Sunday 18 October 2026
Export SRZN’s income statement to Excel — free account
Surrozen, Inc.
SRZN Healthcare Biotechnology
Surrozen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 67.4% from fiscal 2024. In the quarter to June 2026, revenue grew 408.7%, EPS grew 7.84% and free cash flow fell 21.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
23.44
1.63
−6.50%
Follow SRZN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 387.44% | 251.45% | 231.45% | 1,174.85% |
+8 more TTM periods Free account |
|
| (304.47%) | (290.88%) | (328.86%) | (147.62%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(329.55%) | (326.65%) | (294.93%) | (131.93%) | |
Average Days of Receivables |
158.54 | 243.53 | 21.83 | 260.08 | |
Free Cash Flow per Share |
(3.00) | (3.08) | (4.06) | (2.45) | |
Free Cash Flow |
(34.98) | (33.68) | (30.37) | (21.04) | |
Capital Expenditures |
(0.22) | (0.22) | (0.13) | (0.09) | |
| Other line items | |||||
Cash ROIC |
30.00% | 19.67% | 30.83% | (36.39%) | |
Accounts Receivable Turnover |
3.04 | 1.96 | 2.53 | 0.49 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
300.38% | 428.81% | 844.55% | 713.76% | |
Selling, General and Administrative Expense of Revenue |
184.90% | 244.94% | 466.03% | 441.87% | |
Share Based Compensation of Revenue |
60.85% | 68.13% | 110.30% | 103.58% | |
Operating CF/Net income |
0.10 | 0.10 | 0.13 | 0.20 | |
Depreciation/Fixed assets |
0.49 | 0.63 | 1.24 | 5.86 | |
Capex/Depreciation |
(1.00) | (0.72) | (0.24) | (0.11) | |
Revenue per Share |
0.99 | 0.68 | 0.47 | 0.42 | |
Operating CF per Share |
(2.98) | (3.06) | (4.04) | (2.44) | |
Capex per Share |
(0.02) | (0.02) | (0.02) | (0.01) | |
Capex to Sales |
0.02 | 0.03 | 0.04 | 0.02 |
Columns are period end dates